Literature DB >> 15770590

Transanal pull-through for Hirschsprung disease.

Roshni Dasgupta1, Jacob C Langer.   

Abstract

Hirschsprung (HSCR) disease is a relatively common neonatal developmental disorder of the enteric nervous system and is characterized by the absence of ganglion cells in the myenteric and submucosal plexuses of the distal intestine. This results in absent peristalsis in the affected bowel, and the development of a functional intestinal obstruction. The pathogenesis and genetic basis of the disease is yet unclear. The surgical treatment of HSCR has evolved significantly since 1949 when Swenson first proposed a trans-abdominal pull-through procedure. The transanal pull-through consists of a rectal mucosectomy, resection of the aganglionic bowel and a colo-anal anastomosis. Recent literature and clinically controversies of this minimally invasive one-stage procedure are reviewed. Although follow up is still relatively short the preliminary results appear very favorable and cost effective.

Entities:  

Mesh:

Year:  2005        PMID: 15770590     DOI: 10.1053/j.sempedsurg.2004.10.027

Source DB:  PubMed          Journal:  Semin Pediatr Surg        ISSN: 1055-8586            Impact factor:   2.754


  3 in total

1.  Transanal endorectal pull-through for Hirschsprung's disease: experience with 50 patients.

Authors:  Ü Adıgüzel; K Ağengin; I Kırıştıoğlu; H Doğruyol
Journal:  Ir J Med Sci       Date:  2016-03-29       Impact factor: 1.568

2.  Clinical characteristics and management of benign transient non-organic ileus of neonates: a single-center experience.

Authors:  Hye Kyung Chang; Hong Koh; Young Ju Hong; Eun Young Chang; Seok Joo Han; Jung-Tak Oh
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

3.  Transumbilical enterostomy for Hirschsprung's disease with a two-stage laparoscopy-assisted pull-through procedure.

Authors:  Pei-Pei Xu; Xiao-Pan Chang; Xi Zhang; Shui-Qing Chi; Guo-Qing Cao; Shuai Li; De-Hua Yang; Xiang-Yang Li; Shao-Tao Tang
Journal:  World J Gastroenterol       Date:  2019-12-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.